Content related to Cisplatin and Hearing Loss: Until Now, an Unquantified Risk

Researchers at Children’s Hospital Los Angeles led a multi-institutional study that pins down, for the first time, the actual risk of hearing loss from cisplatin, a common chemotherapy agent

A CHLA oncologist led a pivotal clinical trial leading to the approval of the first drug to prevent cisplatin hearing loss in children.

Investigators from Children’s Hospital Los Angeles and 37 other Children’s Oncology Group hospitals in the U.S. and Canada have determined that sodium thiosulfate prevents cisplatin-induced hearing

Investigators at Children’s Hospital Los Angeles have found that chemotherapy-induced hearing loss may also contribute to long-term neurocognitive deficits in pediatric brain tumor survivors.

A new study reveals the value of using clinical and histological characteristics to optimize treatment for hepatoblastoma, a rare liver cancer in children.

Researchers have been delving deeper to better understand long-term cancer survival and quality of life for adolescent and young adult patients.

Risk of detecting cancer cells decreased by 70% after one month of treatment

More than 150 experts worldwide have teamed up to help shape the future of radiation therapy for children with cancer.